Citations for
1CTAG1B, PRAME
Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
Iura K, Kohashi K, Hotokebuchi Y, Ishii T, Maekawa A, Yamada Y, Yamamoto H, Iwamoto Y, Oda Y.
J Pathol Clin Res. Mar 16;1(3):144-59. doi: 10.1002/cjp2.16. eCollection 2015 Jul 2015
2ELOB, ELOC, PRAME
PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs.
Wadelin FR, Fulton J, Collins HM, Tertipis N, Bottley A, Spriggs KA, Falcone FH, Heery DM.
PLoS One 8(2):e58052. doi: 10.1371/journal.pone.0058052. Epub 2013 Feb 27 2013
3PRAME
PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions.
Szczepanski MJ, Deleo AB, Luczak M, Molinska-Glura M, Misiak J, Szarzynska B, Dworacki G, Zagor M, Rozwadowska N, Kurpisz M, Krzeski A, Kruk-Zagajewska A, Kopec T, Banaszewski J, Whiteside TL.
Oral Oncol ral Oncol. 2012 Aug 31. [Epub ahead of print] 2012
4PRAME
The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME.
Costessi A, Mahrour N, Sharma V, Stunnenberg R, Stoel MA, Tijchon E, Conaway JW, Conaway RC, Stunnenberg HG.
PLoS One 7(8):e42822. doi: 10.1371/journal.pone.0042822. Epub 2012 Aug 13. 2012
5PRAME
Expression and prognostic relevance of PRAME in primary osteosarcoma.
Tan P, Zou C, Yong B, Han J, Zhang L, Su Q, Yin J, Wang J, Huang G, Peng T, Shen J.
Biochem Biophys Res Commun 419(4):801-8. Epub 2012 Feb 27. 2012
6PRAME
PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
Brenne K, Nymoen DA, Reich R, Davidson B.
Am J Clin Pathol 137(2):240-7. 2012
7OSGEP, PRAME
The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME.
Costessi A, Mahrour N, Sharma V, Stunnenberg R, Stoel MA, Tijchon E, Conaway JW, Conaway RC, Stunnenberg HG.
PLoS One 7(8):e42822. doi: 10.1371/journal.pone.0042822. Epub 2012 Aug 13. 2012
8PRAME
Insights on PRAME and osteosarcoma by means of gene expression profiling.
Toledo SR, Zago MA, Oliveira ID, Proto-Siqueira R, Okamoto OK, Severino P, Vêncio RZ, Gamba FT, Silva WA, Moreira-Filho CA, Torre CA, Alves MT, Garcia-Filho RJ, Simpson AJ, Petrilli AS.
J Orthop Sci 16(4):458-66. Epub 2011 Jun 21. 2011
9PRAME
Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.
Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T.
Leuk Res 35(9):1219-25. Epub 2011 May 7. 2011
10CUL2, PRAME
The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters.
Costessi A, Mahrour N, Tijchon E, Stunnenberg R, Stoel MA, Jansen PW, Sela D, Martin-Brown S, Washburn MP, Florens L, Conaway JW, Conaway RC, Stunnenberg HG.
EMBO J 30(18):3786-98. doi: 10.1038/emboj.2011.262. 2011
11PRAME
Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.
Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM.
Mol Cancer 9:226. Review. 2010
12PRAME
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E, Ladne P, Stirewalt DL, Abkowitz JL, Radich JP.
Blood 114(15):3299-308. Epub 2009 Jul 22. 2009
13PRAME
PRAME expression in hairy cell leukemia.
Arons E, Suntum T, Margulies I, Yuan C, Stetler-Stevenson M, Kreitman RJ.
Leuk Res 32(9):1400-6. Epub 2008 Mar 4. 2008
14PRAME
Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.
Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP.
Genes Chromosomes Cancer 46(9):796-804. 2007
15PRAME
PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.
Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA, Garcia AB, Rizzatti EG, Nascimento FM, Ishikawa HC, Larson RE, Falcão RP, Simpson AJ, Gout I, Filonenko V, Rego EM, Zago MA.
Leuk Res 30(11):1333-9. Epub 2006 Apr 18. 2006
16PRAME
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.
Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R.
Cell 122(6):835-47. 2005
17PRAME
PRAME gene expression in childhood acute lymphoblastic leukemia.
Steinbach D, Viehmann S, Zintl F, Gruhn B.
Cancer Genet Cytogenet 138(1):89-91. 2002
18MAGEA1, MAGEA3, PRAME
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells.
Pellat-Deceunynck C, Mellerin MP, Labarriere N, Jego G, Moreau-Aubry A, Harousseau JL, Jotereau F, Bataille R.
Eur J Immunol 30(3):803-9. 2000
19ADPRTL4, ADTB1L1, ADTB1L2, ALG12, APOL2, ARHGAP8, ATP6V1E1, BCRL2, BCRL3, BCRL4, BCRL5, BCRL6, BRD1, CBX6, CBY1, CSF2RB2, DRG1, FAM108A5, FAM115B, HMG17L1, HMG17L2, HMGB1L10, INPP5J, MAFF, MAPK11, MPPED1, OSBP2, P2RX6, PATZ1, PITPNB, PPIL2, PRAME, PTPNS1L, RBX1, RHBDD3, RPL32L2, SBF1, SDF2L1, SEZ6L, SFI1, SH3BP1, SNAP29, TBC1D22A, TMEM184B, TOP3B2, TSSK1A, YME1L2, ZNF280A, ZNF280B
The DNA sequence of human chromosome 22.
Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.
Nature 402(6761):489-95. 1999
20PRAME
PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.
van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG.
Br J Haematol 102(5):1376-9. 1998
21OIP5, PRAME, EXOSC8
Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth.
Williams JM, Chen GC, Zhu L, Rest RF.
Mol Microbiol 27(1):171-86. 1998
22PRAME
Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.
Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG.
Immunity 6(2):199-208. 1997